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Abstract: Despite intensive efforts to eradicate the disease, tuberculosis continues to be a 
major threat to Indian society, with an estimated prevalence of 3.45 million cases in 2006. 
Emergence of multidrug-resistant tuberculosis has complicated eradication attempts in recent 
years. Incomplete and/inadequate treatment are the main causes for development of drug resis-
tance. Directly observed therapy, short-course (DOTS) is the World Health Organization (WHO) 
strategy for worldwide eradication of tuberculosis, and our country achieved 100% coverage for 
DOTS through the Revised National Tuberculosis Control Program in 2006. For patients with 
multidrug-resistant tuberculosis, the WHO recommends a DOTS-Plus treatment strategy. Early 
detection and prompt treatment of multidrug-resistant tuberculosis is crucial to avoid spread of 
the disease and also because of the chances of development of potentially incurable extensively 
drug-resistant tuberculosis in these cases. This review discusses the epidemiologic, diagnostic, 
and therapeutic aspects of multidrug-resistant tuberculosis, and also outlines the role of primary 
care doctors in the management of this dangerous disease.
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Introduction
Tuberculosis is among the top three causes of death from a single infectious agent, 
along with malaria and human immunodeficiency virus (HIV). One-third of the world’s 
population is infected with Mycobacterium tuberculosis, the etiologic agent of tuber-
culosis.1 Of the 9.2 million tuberculosis cases reported worldwide in 2006, 0.7 million 
were HIV-positive and 1.7 million cases were fatal, of which 0.2 million occurred 
in HIV-positive people.2 India continues to occupy a unique position with respect to 
the global tuberculosis burden. In 2006, of the 9.2 million new cases of tuberculosis 
reported globally, 1.93 million were reported in India, which constitutes approximately 
one-fifth of the total global burden. This included 0.87 million smear-positive cases 
of the total estimated prevalence and incidence of tuberculosis of 3.45 million and 
1.93 million, respectively, in India for 2006.2
Pulmonary tuberculosis is a highly contagious and life-threatening infection, and 
the mode of spread is droplet infection. The usual source of infection is a human case 
whose sputum is positive for tuberculous bacilli and who has received no treatment 
or has not been treated fully.1 The World Health Organization (WHO) classifies 
tuberculous infection into four categories for the purpose of treating cases effectively 
and in a uniform manner worldwide. In recent years, emergence of multidrug-resistant 
tuberculosis has become a major issue in the successful management and eradication 
of the disease.Infection and Drug Resistance 2010:3 submit your manuscript | www.dovepress.com
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Multidrug-resistant tuberculosis has now reached an 
approximate prevalence rate of 5% of the total global 
tuberculosis burden,3 amounting to half a million cases, 
of which most cases are from Indian, China, and Russia.4,5 
Although the measures adopted by various countries have 
resulted in a 51% case detection rate for tuberculosis and a 70% 
successful treatment rate worldwide, there is still a long way 
to go to achieve a 70% case detection rate and 85% successful 
treatment rate for nonresistant tuberculosis, as suggested by the 
WHO.6 Also, the WHO has suggested 70% case detection and 
treatment rates for multidrug-resistant tuberculosis to curb the 
development of extensively drug-resistant tuberculosis.4 If an 
adequate drug regimen is followed, tuberculosis is considered to 
be 100% curable, as proven to some extent by reduction in the 
case fatality rate from 29% to 4%, under the Revised National 
Tuberculosis Control Program (RNTCP) in India which adopted 
directly observed therapy, short-course (DOTS) in 1993,7 but 
tuberculosis still has a high mortality rate, as evidenced by 
nearly two million deaths every year worldwide.8 To reduce 
this burden further, India is planning to implement DOTS-Plus 
by 2010.7 The incidence of extensively drug-resistant tuberculo-
sis is about 6%–7.3% in patients treated for multidrug-resistant 
tuberculosis worldwide.9,10 Table 1 shows the WHO categories 
of tuberculosis treatment.
Definitions and epidemiology
Multidrug resistance is defined as resistance of M. tuberculosis 
to two or more first-line antituberculous drugs that include iso-
niazid and rifampicin.11 Extensively drug-resistant tuberculosis 
refers to cases of multidrug-resistant tuberculosis which show 
resistance to second-line antituberculous drugs including any 
one of the fluoroquinolones and one of the three injectable 
drugs (amikacin, kanamycin, or capreomycin).12 The most 
recent estimates suggest that globally there were about 489,000 
cases of multidrug-resistant tuberculosis in 2006, of which 
110,132 cases were in India.2 This is about 4.9% of the total 
number of tuberculosis cases in the country. About 0.9%–1.5% 
of multidrug-resistant cases in India may fall into the category 
of extensively drug-resistant tuberculosis.12
Multidrug resistance can be primary or acquired. Primary 
resistance is defined as resistance in patients without a his-
tory or other evidence of previous antituberculous drug 
treatment. Acquired drug resistance occurs in those who 
have previously received antituberculous treatment for at 
least one month and in those with treatment failures and 
relapses. The prevalence of primary multidrug resistance is 
3% and that of acquired multidrug resistance is 12% in India. 
Although drug resistance started appearing in patients with 
M. tuberculosis infection soon after the introduction of effec-
tive antituberculous drugs, multidrug-resistant tuberculosis 
was not a major public health problem until the early 1990s13 
when HIV infection became a global epidemic.
Causes of multidrug-resistant 
tuberculosis
A history of tuberculosis and previous antituberculous 
treatment are the most important factors identified in the 
causation of multidrug-resistant tuberculosis.14 Factors which 
predispose a patient to development of multidrug-resistant 
tuberculosis include:
•	 Incomplete treatment
•	 Inadequate treatment
•	 Errors in tuberculosis management, such as use of a single 
antituberculous drug
•	 Addition of a single drug to a failing regimen
•	 Failure to identify pre-existing resistance
•	 Initiation of an inadequate primary regimen
•	 Failure to identify and address nonadherence to 
treatment
•	 Noncompliance
•	 Inappropriate isoniazid preventive therapy
•	 Variations in bioavailability of antituberculous drugs.15
There are various other factors favoring the spread of 
tuberculosis, which include increasing high-risk groups (eg, 
the elderly, prisoners, immigrants, drug addicts6), recurrent 
defaulters, multidrug-resistant and extensively drug-resistant 
treatment failures,3 increasing age of the general population, 
increasing number of patients with immunosuppression due 
to bone marrow and solid organ transplantation,16 and lack of 
optimal recommended duration of treatment for multidrug-
resistant and extensively drug-resistant tuberculosis in 
controlled clinical trials.4 In addition, certain host genetic 
factors and coexistent HIV infection may also predispose to 
the development of multidrug-resistant tuberculosis.11,17
Table 1 wHO treatment categories for tuberculosis1
Category of 
treatment
Patient
Category I New sputum smear-positive
Seriously ill, sputum smear-negative 
Seriously ill, extrapulmonary
Category II Sputum smear-positive, relapse 
Sputum smear-positive, failure 
Sputum smear-positive treatment after default
Category III Sputum smear-negative, not seriously ill 
extrapulmonary, not seriously ill
Category Iv Multidrug-resistant tuberculosisInfection and Drug Resistance 2010:3 submit your manuscript | www.dovepress.com
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Diagnosis of drug resistance
Drug-resistant tuberculosis needs to be suspected based on 
history of prior treatment (smear-positive cases after repeated 
treatment courses and category II treatment failures), and 
such cases should undergo drug susceptibility testing. 
Lowenstein-Jensen culture is the method traditionally used 
for drug sensitivity testing in tuberculosis.17 A duration of 
6–8 weeks is required before sensitivity results are known 
with this method. Several new methods are now available 
for testing drug sensitivity patterns, but they are costlier 
and are not widely available. The methods for diagnosis of 
multidrug-resistant tuberculosis include:
•	 Conventional (Lowenstein-Jensen) culture, ie, propor-
tional, resistance ratio, absolute concentration
•	 BACTEC-460
•	 Mycobacterial growth indicator tube
•	 E test
•	 Mycobacteriophage method
•	 Molecular methods, ie, polymerase chain reaction, 
ligase chain reaction, restriction fragment length 
polymorphism.11
Identification and proper 
management
Drug marketing surveys done in India for 2006 have shown 
that 75% of the total cost for antituberculous drugs was spent 
outside of the RNTCP, mainly in the private sector.12 The vast 
majority of multidrug-resistant tuberculosis cases might have 
been managed in the private sector in recent years. Improper 
supervision of treatment in the private sector might lead to treat-
ment defaulting and hence incomplete management of cases. 
This may result in development of extensively drug-resistant 
tuberculosis, which is a major public health challenge.12
Multidrug-resistant tuberculosis cases are difficult to 
manage in view of the need for prolonged treatment (up to 
24 months), high rates of treatment failures, higher costs 
and potential toxicities of medications, need for surgery in 
locally confined untreatable cases, and risk of transmission to 
unexposed individuals, including health care workers. Cases 
of extensively drug-resistant tuberculosis may be incurable, 
making the situation worse. A comparison of multidrug-
resistant and extensively drug-resistant tuberculosis is made 
in Table 2.
Treatment
Tuberculosis is a disease with high cure rates if managed 
properly, and an effective national control program can 
reduce the risk of transmission to the unexposed public. 
The Indian tuberculosis control program is now one of the 
largest public health programs in the world.18 The RNTCP 
was established under WHO guidance in 1993. The strategy 
of the RNTCP for control of tuberculosis is DOTS, which is 
familiar to most clinicians now. With extensive efforts on the 
part of government and health departments, India achieved 
a DOTS coverage of 100% in 2006.2 The reported cure rate 
with DOTS treatment was 86% in 2005.2
Management of multidrug-resistant tuberculosis is a 
challenge for clinicians. Adherence to appropriate and pro-
longed drug therapy is the cornerstone of treatment success in 
multidrug-resistant tuberculosis. Hence, the standard DOTS 
regimen may not be helpful for treating these cases.
In low- and middle-income countries that have adopted 
the DOTS strategy, the WHO and its international partners 
have emphasized DOTS-Plus for multidrug resistant tuber-
culosis programs since 1998, in order to promote effective 
treatment of multidrug-resistant tuberculosis.19,20
A comparison between DOTS and DOTS-Plus is shown 
in Table 3. The major differences between DOTS and 
DOTS-Plus are that DOTS employs sputum microscopy 
for diagnosis of tuberculosis cases and multidrug-resistant 
tuberculosis cases, and uses first-line antituberculosis drugs 
over a short period of treatment, while DOTS-Plus uses 
sputum culture and drug sensitivity testing for diagnosis of 
multidrug-resistant tuberculosis cases and uses both first- and 
second-line antituberculous drugs over a longer period of 
time, ie, up to 24 months.11
Only experienced clinicians at centers equipped with 
reliable laboratory services for mycobacterial culture and 
in vitro sensitivity testing should treat multidrug-resistant 
Table 2 Comparison of multidrug-resistant and extensively drug-
resistant tuberculosis
Multidrug-resistant 
tuberculosis
Extensively  
drug-resistant 
tuberculosis
Clinical  
suspicion
First time treated,  
culture-positive at three  
months, or microscopy- 
positive at five months. 
Category II failure cases.  
Default and relapse cases
Treated multidrug- 
resistant patients, with  
no improvement
Resistance 
pattern
Isoniazid, rifampicin ±  
other first-line drugs
Multidrug-resistant 
tuberculosis + any 
fluoroquinolone + at least 
one of the three 
injectable drugs 
(amikacin, kanamycin, 
capreomycin)Infection and Drug Resistance 2010:3 submit your manuscript | www.dovepress.com
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Table 3 Comparison of DOTS and DOTS-Plus11
DOTS DOTS-Plus
Political and 
administrative 
commitment
Yes Yes
Diagnosis by Sputum microscopy Sputum microscopy
Sputum culture and  
drug susceptibility testing
Drugs used First-line 
antituberculous
First-line and second-line 
antituberculous
Duration of therapy Short course 18–24 months
Duration of  
intensive phase  
of treatment
2–3 months Six months
Individualized  
treatment
No Yes
Directly observed Yes Yes
Purpose of therapy Cure tuberculosis  
and prevent 
multidrug resistance
Treat multidrug 
resistance
Monitoring of 
treatment
Monitoring and 
evaluation of 
treatment outcome
Monitoring, reporting, 
and evaluation of 
treatment outcome
tuberculosis cases.17,19 Sputum samples from all suspected 
cases of multidrug-resistant tuberculosis, should be sub-
jected to culture sensitivity and antituberculous drug 
sensitivity testing.11,15,17 Pending results, these patients may 
then be started on WHO category II treatment (under pro-
gram conditions) or the regimens employing various drugs 
(DOTS-Plus).11 Further therapy is guided by the culture and 
sensitivity report.11 A single drug should never be added 
to a failing regimen and, when initiating treatment, at least 
three previously unused drugs with in vitro susceptibility 
must be used.15,21
We need novel drugs and vaccines to be able to face 
the challenges in the treatment of multidrug-resistant and 
extensively drug-resistant tuberculosis. Some of the new 
drugs and vaccines having the potential to cure multidrug-
resistant and extensively drug-resistant tuberculosis are 
linezolid,16,22,23 thioridazine (a neuroleptic phenothiazine),24–26 
myrtle leaf extracts (used as an antiseptic in Sardinian tradi-
tional medicine),27 medicinal plants having antituberculous 
activity (Acalypha indica, Adhatoda vasica, Allium cepa, 
Allium sativum, Aloe vera28), and HSP65+IL-12/HVJ vac-
cine.29 HSP65+IL-12/HVJ is a combination of DNA vac-
cines expressing mycobacterial heat-shock protein 65 and 
interleukin-12, delivered by the hemagglutinating virus of 
Japan envelope and liposome).29 The HSP65+IL-12/HVJ 
vaccine has been shown to have protective and therapeutic 
efficacy in murine models and in Cynomolgus monkeys 
(which are considered to be the best animal model of human 
  tuberculosis). It has also been observed that this vaccine 
exerted therapeutic efficacy (100% survival in Cynomolgus 
monkeys infected with tuberculosis) and showed a synergistic 
effect after an initial priming Bacillus Calmette-Guérin dose. 
The implications of this study are that this vaccine might be 
useful against M. tuberculosis, including multidrug-resistant 
and extensively drug-resistant tuberculosis in humans partici-
pating in therapeutic clinical trials.29 Other agents shown to 
be effective in animal models include a dry powder PA-824 
cyclodextrin-lecithin aerosol suspension.30
Two newer classes of drugs targeting mycobacterial cell 
wall synthesis have been discovered recently, ie, benzothi-
azinones and dinitrobenzamide, which are highly active 
against M. tuberculosis, including extensively drug-resistant 
tuberculosis strains.31
Future inventions include drugs with activity on dif-
ferent bacterial cell wall components, virulence genes, 
small guanosine triphosphatases etc,32 and inhibitors of the 
aspartate kinases involved in bacterial cell wall synthesis.33 
Mutations at hotspots are responsible for the development of 
extensively drug-resistant tuberculosis strains, as observed in 
a study involving 194 M. tuberculosis strains isolated from 
patients.34 Early detection of these extensively drug-resistant 
cases could be done using a rapid test called MTBDRsI, 
which detects resistance to ethambutol, fluoroquinolones, 
second-line aminoglycosides (amikacin and kanamycin), and 
cyclic peptide (capreomycin), and this could be confirmed 
by drug susceptibility testing.35
The principles of treatment (and poor prognostic indica-
tors) for multidrug-resistant tuberculosis include:
•	 Use of as many first-line agents to which the organism is 
sensitive
•	 At least one parenteral drug should be part of the 
regimen
•	 At least three agents to which the isolate is sensitive 
should be used
•	 Administration of oral agents should be directly 
observed
•	 Bactericidal agents should be used whenever possible
•	 Single drugs should never be added to a failing 
regimen.36
Poor prognostic indicators are:
•	 Category II failures given intermittent therapy
•	 Cavity at presentation
•	 HIV positivity
Other factors that predict progression to extensively 
drug-resistant tuberculosis in multidrug-resistant patients are 
bilateral cavitating lesions, prior exposure to a second-line Infection and Drug Resistance 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
119
Multidrug-resistant and extensively drug-resistant tuberculosis
injectable antibiotic, and each additional month in which 
a patient has failed to take at least 80% of their prescribed 
drugs.9 In a recent study, the success rate for treatment was 
87% for multidrug-resistant but not extensively drug-resistant 
tuberculosis, and 41% for extensively drug-resistant cases. In 
this study, resistance to ciprofloxacin, ofloxacin, and amika-
cin is associated with an unsuccessful outcome.37 However, 
DOTS-Plus, which has been found to be an effective strategy 
for treatment of multidrug-resistant tuberculosis showed 
the best cure rates at 70%.2 Monitoring with serial cultures 
should be done at months 4, 6, 12, 18, and 24 of treatment.12 
Treatment for 18–24 months is mandatory in multidrug-
resistant tuberculosis, and the drugs used are costly and have 
higher toxicity rates. Important drugs used for treatment 
of multidrug-resistant tuberculosis and their main adverse 
effects are shown in Table 4.
Prevention strategies
It has been noted worldwide that only 20% of patients with 
tuberculosis receive treatment according to current WHO 
recommendations. The WHO emphasizes and warns that if 
immediate action is not taken to persuade more public health 
authorities and doctors to use the recommended treatment, the 
window of opportunity to prevent the spread of drug-resistant 
strains will be missed.
On the basis of small-scale studies that have used the 
DOTS strategy to prevent the emergence of resistance in 
tuberculosis patients, the WHO has been emphasizing and 
arguing for DOTS for years.38 Measures to prevent the spread 
of multidrug-resistant tuberculosis include:
•	 Cough hygiene
•	 Well-ventilated wards
•	 Segregation of suspected cases
•	 Negative pressure exhausts
•	 Air exchangers and high efficiency particulate arresting 
filters
•	 Personal protection with N95 masks
Apart from these, other measures important in the control 
of the spread of multidrug-resistant and extensively drug-re-
sistant tuberculosis include major improvements in laboratory 
facilities and infection control, improving the performance 
of tuberculosis control programs, better treatment for both 
drug-susceptible and drug-resistant disease, massive scale-up 
in diagnosis and treatment of all types of tuberculosis, newer 
diagnostic tests, newer vaccines, early pulmonary resection 
combined with chemotherapy in multidrug-resistant and 
extensively drug-resistant tuberculosis cases, and commit-
ment on a national scale by countries with the highest tuber-
culosis burden (ie, India, China, and Russia) by improving 
national policies and health systems that remove financial 
barriers to treatment, encourage rational drug usage, and 
create the relevant infrastructure.39
Multidrug-resistant tuberculosis  
in general practice
General practitioners and primary care physicians have key 
roles in the successful management of tuberculosis and thus 
preventing emergence of multidrug resistance in patients. 
Implementation of DOTS in India should be mainly done 
in the primary care setting because most of the population 
reside in rural areas. Timely identification and prompt referral 
of suspected cases to specialty care facilities for DOTS-Plus 
are the main roles of primary care doctors in the manage-
ment of multidrug-resistant tuberculosis. Default from drug 
treatment is one of the major causes of multidrug resistance, 
and hence vigilance should be exercised in handling such 
cases. Figure 1 shows the approach to cases with interrupted 
category II treatment to prevent emergence of multidrug-
resistant tuberculosis.
Factors that are important in making treatment decisions 
for defaulters include duration of treatment interruption (less 
than two weeks, 2–7 weeks, or more than eight weeks), dura-
tion of treatment before interruption (less than one month, 
1–2 months, or more than two months), and the sputum report 
(positive or negative). In all sputum-negative cases, irrespective 
Table 4   Drugs  used  in  the  treatment  of  multidrug-resistant 
tuberculosis11
Group Drugs Important  
adverse effects
Aminoglycosides Streptomycin Nephrotoxicity
Kanamycin Ototoxicity
Amikacin Capreomycin is  
hepatotoxic too
Capreomycin
Thioamides ethionamide Psychosis
Prothionamide Hepatotoxicity
Fluoroquinolones Ofloxacin Gastrointestinal  
disturbances
Levofloxacin Central nervous  
system symptoms
Moxafloxacin
Others Pyrazinamide Hepatotoxicity,  
hyperuricemia
Cycloserine Convulsions,  
suicidal tendency
Para-amino  
salicylic acid
Hepatotoxicity,  
hypersensitivity
ethambutol Optic neuritis,  
peripheral neuritisInfection and Drug Resistance 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
120
Yashodhara et al
of the length of interruption and duration of treatment before 
interruption, it is advisable to continue the remaining months of 
WHO category II treatment. Patients who are sputum-positive 
during treatment of 1–2 months and who had 2–7 weeks of 
interrupted treatment, should take an extra month of intensive   
WHO category II treatment. All remaining sputum-positive 
cases, while on treatment, irrespective of length of interruption 
and/or duration of treatment before interruption, should receive 
a fresh course of WHO category II treatment.1
Conclusion
Emergence  of  multidrug-resistant  and  extensively 
drug-resistant tuberculosis is a major threat to successful 
control of tuberculosis worldwide. Prompt implementation 
of DOTS reduces the chances for development of multidrug-
resistant tuberculosis. Early identification and timely referral 
of suspected multidrug-resistant tuberculosis cases by pri-
mary care doctors for DOTS-Plus treatment will help in the 
appropriate management of multidrug-resistant tuberculosis 
and thereby prevent development of life-threatening exten-
sively drug-resistant disease.
Also, because tuberculosis is compounded by HIV coinfec-
tion, which hastens the emergence of multidrug-resistant and 
extensively drug-resistant tuberculosis, novel   antituberculous 
drugs are urgently required. In this context, the creation of new 
drugs that target metabolic pathways essential for   survival of 
the bacteria, without damaging the host, will prove to be vital. 
It has recently been found that the 2C-methyl-d-erythritol 
4-phosphate (MEP) pathway of M. tuberculosis is one of 
several pathways that are essential for viability of the organ-
ism, and that the human host lacks this particular enzyme, and 
hence treatment targeted to this enzyme would be less toxic 
to humans.40 Thus, the MEP pathway represents a bacterium-
specific drug target and, indeed, fosmidomycin is now known 
to inhibit the second step in the MEP pathway and may lead 
us to find other novel antituberculous drugs.40
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Continuing medical education 
questions
1.   Which of the following statements is/are true regarding 
WHO treatment categories for tuberculosis?
a.    New,  sputum  smear-positive  sample  is WHO 
category I
b.    Seriously ill, sputum smear-negative is WHO 
  category I
c.  Seriously ill, extrapulmonary is WHO category I
d.  Sputum smear-positive relapse is WHO category I.
2.   Which of the following statements is/are true   regarding 
methods used to diagnose multidrug-resistant tuber  culosis?
a.    Mycobacteriophage method is conventional culture 
method
b.    The mycobacterial growth indicator tube is a conven-
tional culture method
c.  Polymerase chain reaction is a molecular method
d.  BACTEC-460 is a molecular method.
3.   Which of the following statements is/are true regarding 
the definition of multidrug-resistant tuberculosis?
a.    It is resistant to isoniazid, rifampicin ± other first-line 
drugs
b.    It is resistant to isoniazid, rifampicin ± other first line 
drugs + an injectable form
c.    It is resistant to isoniazid, rifampicin ± other first-line 
drugs + a fluoroquinolone
d.  It is resistant to a fluoroquinolone and rifampicin.
4.   Which of the following statements best describes the 
purpose of DOTS-Plus?
a.  To cure tuberculosis and prevent multidrug resistance
b. To monitor, report, and evaluate treatment outcome
c.  To make the diagnosis by sputum microscopy
d.    Duration  of  intensive  phase  of  treatment  is 
2–3 months.
5.   Which of these statements predicts poor prognosis in 
multidrug-resistant tuberculosis WHO category II failures 
who received intermittent therapy?
a.  Cavity at presentation
b.  HIV positivity
c.    Sputum culture-positive at three months on optimal 
therapy.
Answers
True:  1.a, 1.b, 1.c, 2.c, 3.a, 4.b, 5.a, 5.b, 5.c.
False:  1.d, 2.a, 2.b, 2.d,